COA Submits Comments on CMS' Proposed CAR T-Cell Coverage Decision
The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy.
The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy, saying that while they are pleased with the direction of covering the therapy, they have concerns with the language included in the memo.
According to COA, CMS should not limit CAR T-cell coverage to hospitals, with many community oncology practices having the experience and capability to administer the therapy. Read the
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Using Targeted Locus Amplification to Analyze Genetically Modified Cells
September 18th 2025
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025